Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CF PharmaTech of Suzhou Raises $65 Million for Inhaled Drug Products

publication date: Aug 28, 2017

Suzhou's CF PharmaTech, a company focused on inhalation products, raised $65 million in a Series D funding. The company operates state-of-art research and manufacturing facilities, compliant with US, EU and China regulations, to develop and make products for China and the world. The company's manufacturing facility is located in Suzhou and its R&D operations are in Wuxi. CF PharmaTech said its latest investment round will expedite submissions for approval of its own pipeline and expand its CDMO services for international clients. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital